Literature DB >> 1373936

Stability and sorption of FK 506 in 5% dextrose injection and 0.9% sodium chloride injection in glass, polyvinyl chloride, and polyolefin containers.

D Taormina1, H Y Abdallah, R Venkataramanan, L Logue, G J Burckart, R J Ptachcinski, S Todo, J J Fung, T E Starzl.   

Abstract

The effects of the diluent, the storage container, light, and infusion through various types of tubing on the stability and sorption of FK 506 were studied. Solutions of FK 506 in 0.9% sodium chloride injection or 5% dextrose injection were stored at room temperature (24 +/- 2 degrees C) in glass i.v. bottles, polyvinyl chloride (PVC) minibags, and polyolefin containers. FK 506 solution in 0.9% sodium chloride injection was stored in plastic syringes at room temperature and either exposed to normal room light or stored in the dark. FK 506 solution in 5% dextrose injection was placed in plastic syringes and infused through PVC anesthesia extension tubing, PVC i.v. administration set tubing, and fat emulsion tubing over a two-hour period. The infused samples and samples collected from the containers and syringes at intervals up to 48 hours were analyzed for FK 506 concentration by high-performance liquid chromatography. FK 506 concentrations remained greater than 90% of initial concentration for admixtures in 5% dextrose injection stored in glass bottles for 48 hours and for admixtures in 5% dextrose injection or 0.9% sodium chloride injection stored in polyolefin containers for 48 hours. No change in concentration was measured for admixtures in 0.9% sodium chloride injection stored in plastic syringes, and exposure to light did not affect the stability of FK 506 solution. No substantial change in concentration occurred in FK 506 solution in 5% dextrose injection infused through PVC anesthesia extension tubing, PVC i.v. administration set tubing, or fat emulsion tubing. FK 506 admixtures prepared with 5% dextrose injection or 0.9% sodium chloride injection should be stored in polyolefin containers. If polyolefin containers are not available, solutions should be prepared with 5% dextrose injection and stored in glass bottles.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373936

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  4 in total

1.  Pharmacokinetics of FK 506 in transplant patients.

Authors:  R Venkataramanan; A Jain; V S Warty; K Abu-Elmagd; M Alessiani; J Lever; A Krajak; J Flowers; S Mehta; S Zuckerman
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

Review 2.  Clinical pharmacokinetics of tacrolimus.

Authors:  R Venkataramanan; A Swaminathan; T Prasad; A Jain; S Zuckerman; V Warty; J McMichael; J Lever; G Burckart; T Starzl
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

Review 3.  Clinical use of tacrolimus (FK-506) in infants and children with renal transplants.

Authors:  D Ellis
Journal:  Pediatr Nephrol       Date:  1995-08       Impact factor: 3.714

4.  Physicochemical Stability of a Novel Tacrolimus Ophthalmic Formulation for the Treatment of Ophthalmic Inflammatory Diseases.

Authors:  Marion Barrieu; Philip Chennell; Mouloud Yessaad; Yassine Bouattour; Mathieu Wasiak; Mireille Jouannet; Yoann Le Basle; Valérie Sautou
Journal:  Pharmaceutics       Date:  2022-01-04       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.